INNOVIVA, INC. Proceeds from Issuance of Debt
INNOVIVA, INC. (INVA) reported Proceeds from Issuance of Debt of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2025-02-26
- INNOVIVA, INC. proceeds from issuance of debt for the quarter ending 2023-12-31 was $0.00.
- INNOVIVA, INC. proceeds from issuance of debt for the quarter ending 2023-09-30 was $0.00.
- INNOVIVA, INC. proceeds from issuance of debt for the quarter ending 2023-06-30 was $0.00.
- INNOVIVA, INC. proceeds from issuance of debt for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- INNOVIVA, INC. proceeds from issuance of debt for fiscal 2024 was $0.00.
- INNOVIVA, INC. proceeds from issuance of debt for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- INNOVIVA, INC. proceeds from issuance of debt for fiscal 2022 was $252.54M.
- INNOVIVA, INC. proceeds from issuance of debt for fiscal 2021 was $0.00.
| Period end | Proceeds from Issuance of Debt 3 month | Proceeds from Issuance of Debt 6 month | Proceeds from Issuance of Debt 9 month | Proceeds from Issuance of Debt 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-26 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | $0.00 10-K · filed 2025-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $0.00 derived: sum of 2 quarters · filed 2023-11-01 | $0.00 10-Q · filed 2023-11-01 | $0.00 derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $0.00 10-Q · filed 2023-08-02 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | $0.00 derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | -$256.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | -$256.00K derived: sum of 3 quarters · filed 2025-02-26 | $252.54M 10-K · filed 2025-02-26 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$256.00K derived: sum of 2 quarters · filed 2023-11-01 | $252.54M 10-Q · filed 2023-11-01 | $252.54M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | -$256.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $252.54M 10-Q · filed 2023-08-02 | $252.54M derived: sum of 3 quarters · filed 2024-03-05 | $252.54M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $252.79M 10-Q · filed 2023-05-09 | $252.79M derived: sum of 2 quarters · filed 2024-03-05 | $252.79M derived: sum of 3 quarters · filed 2024-03-05 | $252.79M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-05 | $0.00 derived: sum of 2 quarters · filed 2024-03-05 | $0.00 derived: sum of 3 quarters · filed 2024-03-05 | $0.00 10-K/A · filed 2024-03-05 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | $0.00 10-Q · filed 2022-07-27 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |